Built to a standard, not a minimum.
Every Biohacker compound moves through four stages: synthesis, encapsulation, independent verification, dispatch. Nothing leaves without passing all four. Each stage is a gate, not a formality.
Each lot carries a unique identifier from raw amino acid intake to finished capsule. That identifier links to a COA, a production run, and a ship date — published and verifiable. You are not taking our word for it. You are reading the data.
Synthesis
Peptide chains built from pharmaceutical-grade amino acids. Full lot traceability from raw material intake.
Encapsulation
Active compound sealed in enteric polymer. Coat formulated per compound class for duodenal-pH release.
Third-Party Verification
HPLC purity, ESI-MS mass confirmation, ICP-MS heavy metal screen. All conducted by independent laboratory.
Dispatch
Lot-coded, tamper-evident packaging shipped same day as QA sign-off. COA published concurrently.
The performance case for purity.
Peptides work by binding to specific receptors and triggering precise biological cascades. That precision only holds when the compound is exactly what it claims to be. A 95% pure peptide is not 95% effective — the remaining fraction competes for binding sites, introduces off-target activity, and caps what the active dose can achieve.
Our 99%+ purity floor is not a marketing metric. It is what clean pharmacology requires.
Bioavailability, engineered.
Oral peptide delivery fails at two points: the stomach destroys most compounds before they reach the intestine, and even intact peptides struggle to cross the gut wall. We engineered past both. Enteric encapsulation protects the compound from gastric acid and triggers release at duodenal pH. A permeation-enhancer matrix, formulated per compound class, drives absorption across the intestinal epithelium.
Every formulation is validated against the injected reference standard. No needles. No compromise on outcome.
Compounds, selected on signal.
The Biohacker catalogue is narrow by design. Every compound carries a defensible body of clinical or preclinical literature — metabolic regulators, tissue-repair peptides, nootropic fragments, longevity candidates. We stock evidence, not trends.
If the signal exists, it is here. If it does not, it is not.
